Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($)	1 Months Ended						3 Months Ended		12 Months Ended
	Feb. 28, 2025	Oct. 31, 2024	Jan. 31, 2024	Jan. 31, 2020	Sep. 30, 2017	Feb. 28, 2015	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2018	Feb. 28, 2023
License And Collaboration Agreements [Line Items]
Licenses revenue							$ 42,017,000	$ 56,519,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							41,035,000	55,156,000
Mochida Pharmaceutical Co., Ltd. \| In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000		$ 1,000,000
Mochida Pharmaceutical Co., Ltd. \| In-licenses \| Research and Development Expense
License And Collaboration Agreements [Line Items]
Up-front payment										$ 2,700,000
Edding \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received						$ 15,000,000
Sales-based milestone event payment							120,000,000
Edding \| Out-licenses \| Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue							40,081,000		$ 40,081,000
Edding \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							0	3,400,000
Edding \| Out-licenses \| Maximum
License And Collaboration Agreements [Line Items]
Sales-based milestone event payment							50,000,000
Edding \| Out-licenses \| Minimum
License And Collaboration Agreements [Line Items]
Sales-based milestone event payment							5,000,000
Biologix FZCo \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue								0
Biologix FZCo \| Out-licenses \| Maximum \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							100,000
HLS \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received					$ 5,000,000
Non-refundable milestone payment received				$ 3,800,000
HLS \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							0	1,900,000
HLS \| Out-licenses \| Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone					$ 50,000,000
CSL Seqirus \| Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received		$ 500,000
Non-refundable milestone payment received		1,200,000
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone		1,200,000
Upfront payment receivable											$ 500,000
Event-related milestone payments receivable		6,000,000
Additional product-related milestone payments receivable		$ 4,000,000
CSL Seqirus \| Out-licenses \| Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue							0	0
CSL Seqirus \| Out-licenses \| Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue							$ 0	$ 0